These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15792402)

  • 21. Self-assembly of peptide-amphiphile nanofibers: the roles of hydrogen bonding and amphiphilic packing.
    Paramonov SE; Jun HW; Hartgerink JD
    J Am Chem Soc; 2006 Jun; 128(22):7291-8. PubMed ID: 16734483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymeric gadolinium chelate magnetic resonance imaging contrast agents: design, synthesis, and properties.
    Ladd DL; Hollister R; Peng X; Wei D; Wu G; Delecki D; Snow RA; Toner JL; Kellar K; Eck J; Desai VC; Raymond G; Kinter LB; Desser TS; Rubin DL
    Bioconjug Chem; 1999; 10(3):361-70. PubMed ID: 10346865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The challenge of T1 contrast agents for high-magnetic field MRI.
    Helm L
    Chimia (Aarau); 2011; 65(9):696-8. PubMed ID: 22026182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of molecular descriptors in the design of gadolinium (III) chelates as MRI contrast agents.
    Maiocchi A
    Mini Rev Med Chem; 2003 Dec; 3(8):845-59. PubMed ID: 14529503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gadolinium meets medicinal chemistry: MRI contrast agent development.
    Zhang Z; Nair SA; McMurry TJ
    Curr Med Chem; 2005; 12(7):751-78. PubMed ID: 15853710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-Targeted and Clearable Human Protein-Based MRI Nanoprobes.
    Zhao Y; Peng J; Li J; Huang L; Yang J; Huang K; Li H; Jiang N; Zheng S; Zhang X; Niu Y; Han G
    Nano Lett; 2017 Jul; 17(7):4096-4100. PubMed ID: 28581764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptide-based building blocks as structural elements for supramolecular Gd-containing MRI contrast agents.
    Diaferia C; Gianolio E; Accardo A
    J Pept Sci; 2019 May; 25(5):e3157. PubMed ID: 30767370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-relaxivity MRI contrast agents: where coordination chemistry meets medical imaging.
    Werner EJ; Datta A; Jocher CJ; Raymond KN
    Angew Chem Int Ed Engl; 2008; 47(45):8568-80. PubMed ID: 18825758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tris(pyrone) chelates of Gd(III) as high solubility MRI-CA.
    Puerta DT; Botta M; Jocher CJ; Werner EJ; Avedano S; Raymond KN; Cohen SM
    J Am Chem Soc; 2006 Feb; 128(7):2222-3. PubMed ID: 16478170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Environment-sensitive and enzyme-sensitive MR contrast agents.
    Querol M; Bogdanov A
    Handb Exp Pharmacol; 2008; (185 Pt 2):37-57. PubMed ID: 18626598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hydrophobic-region-induced transitions in self-assembled peptide nanostructures.
    Xu H; Wang J; Han S; Wang J; Yu D; Zhang H; Xia D; Zhao X; Waigh TA; Lu JR
    Langmuir; 2009 Apr; 25(7):4115-23. PubMed ID: 19714895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioresponsive, cell-penetrating, and multimeric MR contrast agents.
    Major JL; Meade TJ
    Acc Chem Res; 2009 Jul; 42(7):893-903. PubMed ID: 19537782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multimeric Near IR-MR Contrast Agent for Multimodal In Vivo Imaging.
    Harrison VS; Carney CE; MacRenaris KW; Waters EA; Meade TJ
    J Am Chem Soc; 2015 Jul; 137(28):9108-16. PubMed ID: 26083313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Self-assembly of fibronectin mimetic peptide-amphiphile nanofibers.
    Rexeisen EL; Fan W; Pangburn TO; Taribagil RR; Bates FS; Lodge TP; Tsapatsis M; Kokkoli E
    Langmuir; 2010 Feb; 26(3):1953-9. PubMed ID: 19877715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural and relaxometric characterization of peptide aggregates containing gadolinium complexes as potential selective contrast agents in MRI.
    Vaccaro M; Mangiapia G; Paduano L; Gianolio E; Accardo A; Tesauro D; Morelli G
    Chemphyschem; 2007 Dec; 8(17):2526-38. PubMed ID: 17960748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stability of linear and macrocyclic gadolinium based contrast agents.
    Schmitt-Willich H
    Br J Radiol; 2007 Jul; 80(955):581-2; author reply 584-5. PubMed ID: 17704318
    [No Abstract]   [Full Text] [Related]  

  • 37. Implementation of P22 viral capsids as intravascular magnetic resonance T1 contrast conjugates via site-selective attachment of Gd(III)-chelating agents.
    Min J; Jung H; Shin HH; Cho G; Cho H; Kang S
    Biomacromolecules; 2013 Jul; 14(7):2332-9. PubMed ID: 23758486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell-penetrating peptides and peptide nucleic acid-coupled MRI contrast agents: evaluation of cellular delivery and target binding.
    Mishra R; Su W; Pohmann R; Pfeuffer J; Sauer MG; Ugurbil K; Engelmann J
    Bioconjug Chem; 2009 Oct; 20(10):1860-8. PubMed ID: 19788302
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surfactant-assisted synthesis of nanoscale gadolinium metal-organic frameworks for potential multimodal imaging.
    Taylor KM; Jin A; Lin W
    Angew Chem Int Ed Engl; 2008; 47(40):7722-5. PubMed ID: 18767098
    [No Abstract]   [Full Text] [Related]  

  • 40. Enzymatic activation of cell-penetrating peptides in self-assembled nanostructures triggers fibre-to-micelle morphological transition.
    Shi Y; Hu Y; Ochbaum G; Lin R; Bitton R; Cui H; Azevedo HS
    Chem Commun (Camb); 2017 Jul; 53(52):7037-7040. PubMed ID: 28613294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.